 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
17 News |  |
- | alirinetide (GM604) / Genervon
Journal: GM6 attenuates Alzheimer's disease pathology through a reduction in fibrinogen levels and by regulation of Aβ, p-tau and inflammation. (Pubmed Central) - Feb 4, 2022
In conclusion, to counter the additive adverse effect on cognition from vascular dysfunction and amyloid burden, GM6 may be a feasible approach to attenuate Alzheimer's disease pathology through a reduction in fibrinogen levels and by regulation of Ab, p-tau and inflammation.
- alirinetide (GM604) / Genervon
[VIRTUAL] GM6 attenuates Alzheimer’s disease pathology through a reduction in fibrinogen levels and by regulation of Ab, p-tau and inflammation. () - Aug 2, 2021 - Abstract #AAIC2021AAIC_2431;
In conclusion, to counter the additive adverse effect on cognition from vascular dysfunction and amyloid burden, GM6 may be a feasible approach to attenuate Alzheimer's disease pathology through a reduction in fibrinogen levels and by regulation of Ab, p-tau and inflammation. In conclusion, to counter the additive adverse effect on cognition from vascular dysfunction and amyloid burden, GM6 may be a feasible approach to attenuate Alzheimer’s disease pathology through a reduction in fibrinogen levels and by regulation of Ab, p-tau and inflammation.
- || GM604 / Genervon
FDA event: It is definitely do-able. We had a petition from ALS community to FDA for GM604 approval - over 800,000 supporters 👍. https://t.co/HVz7BLwhHg (Twitter) - Jul 10, 2019
- | GM602 / Genervon
Trial completion, Trial primary completion date: GMAIS: Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours (clinicaltrials.gov) - Aug 2, 2017
P2, N=34, Completed, Sponsor: Genervon Biopharmaceuticals, LLC
In conclusion, to counter the additive adverse effect on cognition from vascular dysfunction and amyloid burden, GM6 may be a feasible approach to attenuate Alzheimer’s disease pathology through a reduction in fibrinogen levels and by regulation of Ab, p-tau and inflammation. Recruiting --> Completed | Trial primary completion date: Jun 2017 --> Jul 2016
- GM602 / Genervon
Trial primary completion date: GMAIS: Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours (clinicaltrials.gov) - Aug 22, 2016
P2, N=36, Recruiting, Sponsor: Genervon Biopharmaceuticals, LLC
Recruiting --> Completed | Trial primary completion date: Jun 2017 --> Jul 2016 Trial primary completion date: Dec 2016 --> Jun 2017
- GM602 / Genervon
Trial primary completion date: GMAIS: Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours (clinicaltrials.gov) - Aug 20, 2015
P2, N=36, Recruiting, Sponsor: Genervon Biopharmaceuticals, LLC
Trial primary completion date: Dec 2016 --> Jun 2017 Trial primary completion date: Mar 2014 --> Dec 2016
- | alirinetide (GM604) / Genervon
Trial completion: GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS) (clinicaltrials.gov) - Aug 20, 2015
P2a, N=12, Completed, Sponsor: Genervon Biopharmaceuticals, LLC
Trial primary completion date: Mar 2014 --> Dec 2016 Active, not recruiting --> Completed
- GM608 / Genervon
Trial completion, Trial primary completion date: Phase 2A Study of GM 608 in Mild to Moderate Parkinson Disease (clinicaltrials.gov) - Aug 20, 2015
P2a, N=6, Completed, Sponsor: Genervon Biopharmaceuticals, LLC
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Dec 2013 --> Jul 2014
- | alirinetide (GM604) / Genervon
Enrollment closed: GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS) (clinicaltrials.gov) - Feb 9, 2014
P2a, N=12, Active, not recruiting, Sponsor: Genervon Biopharmaceuticals, LLC
Recruiting --> Completed | Trial primary completion date: Dec 2013 --> Jul 2014 Recruiting --> Active, not recruiting
- | alirinetide (GM604) / Genervon
New P2a trial: GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS) (clinicaltrials.gov) - May 13, 2013
P2a, N=12, Active, not recruiting, Sponsor: Genervon Biopharmaceuticals, LLC
- GM608 / Genervon
New P2a trial: Phase 2A Study of GM 608 in Mild to Moderate Parkinson Disease (clinicaltrials.gov) - May 7, 2013
P2a, N=6, Recruiting, Sponsor: Genervon Biopharmaceuticals, LLC
- | GM602 / Genervon
Trial initiation date: GMAIS: Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours (clinicaltrials.gov) - Apr 10, 2012
P2, N=36, Recruiting, Sponsor: Genervon Biopharmaceuticals, LLC
Recruiting --> Active, not recruiting Initiation date: Feb 2010 --> Feb 2011